Distributor WIZ Dispenser   Advisory Board

Distributor CI Dispenser   Advisory Board

Distributor CLD Dispenser   Advisory Board

Distributor CD1 Dispenser   Advisory Board

Distributor FAQ1 Dispenser   Advisory Board

ZERAMAX™ Advisory Board

The ZERAMAX™ Advisory Board consists of medical professionals with many years of clinical and research experience.  The members are:

 

Cesar A. Albarracin, M.D.

Dr. Albarracin is a Board Certified Internist who has been in private practice for the past 16 years in Corpus Christi, Texas.  With his main interests in diabetes management and education, Dr. Albarracin’s practice is mainly focused on diabetic patients, and he has had great success helping them to control their A1c levels.  Dr. Albarracin is a member of the American Diabetes Association, and has recently been recognized as a Fellow of the American College of Physicians.

Dr. Albarracin is a Certified Principal Investigator and has participated in several clinical trials in diabetes.  He was the lead author in the clinical trial “Chromium picolinate and biotin combination improves glucose metabolism in treated, uncontrolled overweight to obese patients with type 2 diabetes” which was published in Diabetes Metabolism Research and Reviews 2008; 24(1):41-51.

 

Barry H. Ginsberg, M.D., Ph.D.

Dr. Ginsberg is the President of Diabetes Technology Consultants. Previously, he was Vice President for WorldWide Medical Affairs for the Diabetes Division of BD Medical Systems, where he led the medical aspects of the diabetes program for 17 years. Dr. Ginsberg is an internationally recognized expert on diabetes, blood glucose monitoring, and implantable sensors. He is the recipient of a Lifetime Achievement Award from BD. Dr. Ginsberg joined BD from the University of Iowa, where he was professor of internal medicine and biochemistry. He was the Principle Investigator of the Diabetes Control and Complications Trial (DCCT) and for part of the time led its ancillary research committee. He has published over 100 articles in peer-reviewed journals and has received over 5 million dollars in research grants. Dr. Ginsberg also has expertise in computers and on the data reduction, analysis, and usage of glucose monitoring data.

Dr. Ginsberg has an undergraduate degree with highest honors in chemistry from Harpur College, SUNY Binghamton, and an M.D. and Ph.D. in Molecular Biology from Albert Einstein College of Medicine. His medical training in internal medicine was obtained at Beth Israel Hospital (Boston), a Harvard primary teaching hospital, and his training in Endocrinology and Diabetes was done at the Diabetes Branch of the NIH.

 

Ivan Herstik, D.P.M., D.A.B.P.S.

Dr. Herstik was section chief of Podiatry/Department of Orthopedics at St. Vincent’s Hospital Medical Center- Manhattan until the hospital closed in 2010. With more than 25 years of experience, Dr. Herstik understands the importance of total medical management of pedal conditions.  His practice includes counseling patients on conservatively treating all symptoms and manifestations of diseases, which may include diet, exercise and supplements.  He believes counseling and educating patients is the most important part of the treatment. He is Board Certified in Podiatric Surgery.  He lectures locally and nationally on Foot Surgery and treatment.

Dr. Herstik graduated from the New York College of Podiatric Medicine in1987, completing a two-year Residency in foot surgery at Kern Hospital for Special Surgery, in Warren, Michigan.

 

Lawrence S. (Larry) Olanoff, M.D., Ph.D.

Dr. Olanoff is Special Advisor to the President for Corporate Relations at the Medical University of South Carolina (MUSC). After a long career in the pharmaceutical industry, he retired from his last position as President and Chief Operating Officer (2006-2010) at Forest Laboratories, Inc., and currently serves as a Director of Forest Laboratories, Inc. He also serves as Chairman of the Board of Ariel Pharmaceuticals, a member of the Advisory Board of BioMotiv, and is an ex-officio member of the MUSC Foundation for Research Development Board.

Dr. Olanoff was President and Chief Executive Officer of Celsion Corporation from 2005 to 2006. From 1995 until 2005, Dr. Olanoff was responsible for the leadership of research and development activities for Forest Laboratories, Inc., ultimately as its Executive Vice President-Scientific Affairs. From 1993 to 1995, Dr. Olanoff was Senior Vice President-Clinical Research and Development at Sandoz Pharmaceutical Corporation. From 1984 to 1993, Dr. Olanoff was employed by The Upjohn Company, where his last position was Corporate Vice President-Clinical Development and Medical Affairs.

Dr. Olanoff holds M.D. and Ph.D. (Biomedical Engineering) degrees from Case Western Reserve University and was a medical resident and clinical pharmacology fellow at MUSC. He is the author or co-author of numerous scientific publications in the fields of clinical pharmacology, drug delivery, and pharmacokinetics.

 

Nadem J. Sayegh, M.D.

Dr. Sayegh is an Endocrinologist with two private practices in Yonkers, NY, and a third in Bronx, NY.  A member of the American Medical Association and the American Diabetes Association, Dr. Sayegh’s interests include endocrinology and metabolism, diabetes management, obesity management and growth hormone therapy.

Dr. Sayegh served as the President of the Medical Board at St. Joseph’s Medical Center in Yonkers, NY and as Medical Director for the Terrace Health Center in Bronx, NY.  He has also served as Medical Director for several Long Term Care facilities in the New York area, including the Westchester Center for Independent & Assisted Living, the Bronx Park Rehabilitation and Nursing Center, the Westchester Center for Rehabilitation & Nursing, and the Methodist Home for the Aging.

Dr. Sayegh completed his residency training and fellowship in endocrinology and metabolism at the Lincoln Medical Center and Mental Health Center, Bronx, NY.  He received his medical degree from Spartan Health Science University, St. Lucia.